Tsui Kailok - Lees Pharmaceutical Group Officer
| LPCUFDelisted Stock | USD 0.0001 0.00 0.00% |
Insider
Tsui Kailok is Group Officer of Lees Pharmaceutical Holdings
| Age | 56 |
| Phone | 852 2314 1282 |
| Web | https://www.leespharm.com |
Lees Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0591 % which means that it generated a profit of $0.0591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0531) %, meaning that it generated substantial loss on money invested by shareholders. Lees Pharmaceutical's management efficiency ratios could be used to measure how well Lees Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Lees Pharmaceutical Holdings has accumulated 84.09 M in total debt with debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. Lees Pharmaceutical has a current ratio of 1.02, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Lees Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Lees Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lees Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lees to invest in growth at high rates of return. When we think about Lees Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Justine Tan | Keurig Dr Pepper | 46 | |
| Monique Oxender | Keurig Dr Pepper | 48 | |
| Robbie Madan | SNDL Inc | 45 | |
| Wojciech Hlibowicki | Rumble Inc | 41 | |
| Rodrigo Rueda | Sapiens International | N/A | |
| Zachary IV | SNDL Inc | 46 | |
| Tyson Seely | Keurig Dr Pepper | N/A | |
| Gary Sherne | Sapiens International | N/A | |
| Nelson Urdaneta | Keurig Dr Pepper | 47 | |
| Juliette Hickman | Keurig Dr Pepper | 46 | |
| Dina Vince | Sapiens International | N/A | |
| Debra Sandler | Keurig Dr Pepper | 60 | |
| Mary DeNooyer | Keurig Dr Pepper | 54 | |
| Christopher Pavlovski | Rumble Inc | 40 | |
| Brandon Alexandroff | Rumble Inc | 45 | |
| Mauricio Arboleda | Keurig Dr Pepper | 54 | |
| Justin Whitmore | Keurig Dr Pepper | 41 | |
| Tony Milikin | Keurig Dr Pepper | 60 | |
| Andrew Stordeur | SNDL Inc | 44 | |
| Claudio Ramolo | Rumble Inc | 36 | |
| James Keough | SNDL Inc | 60 | |
Management Performance
| Return On Equity | -0.0531 | |||
| Return On Asset | 0.0591 |
Lees Pharmaceutical Leadership Team
Elected by the shareholders, the Lees Pharmaceutical's board of directors comprises two types of representatives: Lees Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lees. The board's role is to monitor Lees Pharmaceutical's management team and ensure that shareholders' interests are well served. Lees Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lees Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yueshen Chen, COO, Deputy General Manager of Zhaoke Pharmaceutical (Hefei) Co. Ltd and Director of Zhaoke Pharmaceutical (Hefei) Co. Ltd | ||
| Yuanjue Sun, Chief Officer | ||
| Zhongyu Jiao, Chief Officer of Enterprise Development Department of the Group | ||
| Wanee Leelalertsuphakun, Chief Marketing and Sales Officer, Managing Director, Executive Director and Member of Remuneration Committee | ||
| Tsui Kailok, Group Officer | ||
| Yiu Chow, CFO and Company Secretary | ||
| Siu Lee, Chairman and Compliance Officer | ||
| Xiaoyi Li, CEO, Chief Technical Officer and Executive Director |
Lees Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Lees Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0531 | |||
| Return On Asset | 0.0591 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (1.58) % | |||
| Current Valuation | 123.64 M | |||
| Shares Outstanding | 588.84 M | |||
| Shares Owned By Insiders | 63.62 % | |||
| Shares Owned By Institutions | 6.36 % | |||
| Price To Book | 0.0002 X | |||
| Price To Sales | 0.10 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Lees Pink Sheet
If you are still planning to invest in Lees Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lees Pharmaceutical's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |